Skip to main content

Flagship Communities Real Estate Investment Trust Announces July 2026 Cash Distribution

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, July 15, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX:MHC.U) (TSX:MHC.UN) today announced a cash distribution of US$0.0545 per REIT unit for the month of July 2026, representing US$0.654 per REIT unit on an annualized basis. Payments will be made on or about August 17, 2026, to unitholders of record as of the close of business on July 31, 2026. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstance. About Flagship Communities Real Estate Investment...

Continue reading

Nuvini Appoints Rodrigo Natale as Chief Financial Officer

Appointment effective July 20th, 2026, completing the CFO search opened in February 2026; Mr. Natale has been a shareholder in the Company since 2020 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a serial acquirer and operator of profitable B2B software companies in the Americas, today announced the appointment of Rodrigo Natale as Chief Financial Officer, effective July 15, 2026. The appointment completes a CFO search the Company initiated in February 2026 and adds dedicated senior financial oversight and governance to a Company that operates a portfolio of seven B2B SaaS businesses serving more than 22,400 customers. Key facts of the appointment:Role: Chief Financial Officer, effective July 20, 2026. Mr. Natale will report to the Chief Executive Officer. Relationship...

Continue reading

OTC Markets and Elysium Connect OTC Link ATS to Digital Asset Custodians

Elysium’s MatchHub will bridge OTC Link ATS and digital asset custodians, closing the interoperability gap between market structures NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, and Elysium LD Technology Inc. today announced a new integration which connects OTC Link ATS, OTC Markets’ regulated trading system, with digital asset custodians, the firms that securely hold digital asset securities for institutions. The traditional finance and digital asset ecosystems were built on different frameworks, using technologies and protocols not designed to work together. This integration addresses that gap by enabling direct message connectivity between OTC Link ATS and digital asset custodians. The connection is powered by MatchHub,...

Continue reading

MariMed Announces Second Quarter 2026 Earnings Date

NORWOOD, Mass., July 15, 2026 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its second quarter 2026 financial results on August 12, 2026 after the markets close. Management will host a conference call on August 13, 2026 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q2 2026 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website. About MariMedMariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands,...

Continue reading

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office. Dr. Jenkins has spent over 20 years working in the biopharmaceutical industry and brings broad experience leading R&D and external innovation programs across a range of therapeutic areas, development stages...

Continue reading

Pet Valu Announces Timing of Second Quarter 2026 Earnings Release

MARKHAM, Ontario, July 15, 2026 (GLOBE NEWSWIRE) — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, will release its financial results for the second quarter of fiscal 2026 on Tuesday, August 11, 2026 at approximately 6:30am ET, followed by a live webcast and conference call at 8:30am ET. The live webcast can be accessed through the Events & Presentations section of the Company’s website at investors.petvalu.ca. Participants can also dial-in to the conference call by pre-registering using this link. Registrants will receive an email, including dial-in details and a unique access code required to join the live call. Please ensure you have registered at least 15 minutes prior to the conference call time. For those unable to attend,...

Continue reading

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The FDA also indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. About Narcolepsy Narcolepsy is a serious and debilitating orphan neurological condition that causes dysregulation of the sleep-wake cycle and is characterized clinically by excessive daytime...

Continue reading

Portillo’s Doubles Down in Hometown City of Chicago with New Wrigleyville Restaurant

Chicago-born brand celebrates National Hot Dog Day by announcing plans to open its newest restaurant in the Wrigleyville neighborhood and inviting Chicagoland fans to a special Hot Dog Season pop-up celebration, just steps from the ballpark OAK BROOK, Ill., July 15, 2026 (GLOBE NEWSWIRE) — On the holiday that celebrates the food that made it famous, Portillo’s (NASDAQ: PTLO) today announced it will open a new restaurant location in the heart of Wrigleyville, further doubling down on its commitment to serving its hometown. Timed to National Hot Dog Day (July 15), the announcement brings the iconic Chicago-born brand to one of the city’s most beloved neighborhoods, where baseball fans and residents alike have long requested a Portillo’s restaurant. “There’s no better day to announce a new Portillo’s location than National Hot Dog...

Continue reading

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor...

Continue reading

GXO To Host 2026 Investor Day

GREENWICH, Conn., July 15, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced it will host its 2026 Investor Day on Monday, November 16, at the New York Stock Exchange. The in-person event will begin at 9:00 a.m. Eastern Time and will also be webcast live. The event will feature presentations from GXO CEO Patrick Kelleher, CFO Mark Suchinski and members of the executive leadership team on the company’s long-term strategy, financial framework and value creation opportunities. The webcast and presentation materials will be available on the Company’s Investor Relations website at investors.gxo.com. A replay will be available following the event. About GXO GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.